复宏汉霖(02696.HK)与Palleon订立合作及许可协议

阿斯达克财经00:30

复宏汉霖(02696.HK) 公布，与Palleon订立合作及许可协议，据此，双方同意就E-602及联合疗法用于人类疾病治疗的全球合作开发及于各自许可区域内的商业化作出约定。本次合作不涉及首付款，公司将向Palleon支付里程碑款项合计不超过9,530万美元，以及以年度净销售额8%-12%计的特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-19 16:25。)

AASTOCKS新闻

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492106308?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg","is_english":false,"pubTime":"2024-12-20 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492106308","market":"other","top_or_hot":-1,"title":"复宏汉霖(02696.HK)与Palleon订立合作及许可协议","media":"阿斯达克财经","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>(02696.HK)<span> </span>公布，与Palleon订立合作及许可协议，据此，双方同意就E-602及联合疗法用于人类疾病治疗的全球合作开发及于各自许可区域内的商业化作出约定。本次合作不涉及首付款，公司将向Palleon支付里程碑款项合计不超过9,530万美元，以及以年度净销售额8%-12%计的特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-19 16:25。)<br/><br/></p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖(02696.HK)与Palleon订立合作及许可协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖(02696.HK)与Palleon订立合作及许可协议\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯达克财经</strong><span class=\"h-time small\">2024-12-20 00:30</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div> <span> <p><a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>(02696.HK)<span> </span>公布，与Palleon订立合作及许可协议，据此，双方同意就E-602及联合疗法用于人类疾病治疗的全球合作开发及于各自许可区域内的商业化作出约定。本次合作不涉及首付款，公司将向Palleon支付里程碑款项合计不超过9,530万美元，以及以年度净销售额8%-12%计的特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-19 16:25。)<br/><br/></p><div></div>AASTOCKS新闻 </span> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405369/latest-news/AAFN\">阿斯达克财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405369/latest-news/AAFN","article_id":"2492106308","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492106308","pubTimestamp":1734625800,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"复宏汉霖(02696.HK) 公布，与Palleon订立合作及许可协议，据此，双方同意就E-602及联合疗法用于人类疾病治疗的全球合作开发及于各自许可区域内的商业化作出约定。本次合作不涉及首付款，公司将向Palleon支付里程碑款项合计不超过9,530万美元，以及以年度净销售额8%-12%计的特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-19 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02696":"复宏汉霖","BK1161":"生物科技"},"translate_title":"Henlius (02696. HK) enters into cooperation and licensing agreement with Palleon","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"复宏汉霖(02696.HK) 公布，与Palleon订立合作及许可协议，据此，双方同意就E-602及联合疗法用于人类疾病治疗的全球合作开发及于各自许可区域内的商业化作出约定。本次合作不涉及首付款，公司将向Palleon支付里程碑款项合计不超过9,530万美元，以及以年度净销售额8%-12%计的特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-19 16:25。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492106308"}